Even as WHO supported Solidarity Therapeutics Trial found remdesivir to be ineffective in reducing mortality and duration of hospital stay, the global body prequalified the drug the same day the results of the trial were posted on the preprint server. And Gilead Sciences, which was aware of the Solidarity trial results, signed a $1 billion … Continue reading WHO supported Solidarity trial finds remdesivir ineffective but WHO prequalifies it anyway
Gilead Sciences
Remdesivir, other repurposed drugs ineffective, says WHO’s Solidarity trial
WHO's Solidarity Therapeutics Trial, the largest randomised control trial carried out in the world during the pandemic, has found that four repurposed drugs — remdesivir, interferon, hydroxychloroquine and lopinavir/ritonavir regimes — for the treatment of COVID-19 are not effective. WHO's Solidarity Therapeutics Trial, the largest randomised control trial carried out in the world during the … Continue reading Remdesivir, other repurposed drugs ineffective, says WHO’s Solidarity trial
Gilead to begin testing inhaled remdesivir for early-stage treatment
Gilead plans to begin a Phase-1 clinical trial in August of an inhaled version of remdesivir for early-stage COVID-19 treatment outside of hospital settings. The drug is currently approved for daily intravenous administration in the hospital. With an approval from the U.S. FDA in hand, Gilead hopes to begin a Phase-1 clinical trial in August … Continue reading Gilead to begin testing inhaled remdesivir for early-stage treatment
Remdesivir trial results: NEJM, NIAID and Gilead provide conflicting information
Information shared by the three stakeholders — NEJM, NIAID and Gilead — on critical issues about whether the drug's ability to reduce mortality is statistically significant and which category of patients benefit and who don't stand to gain is both confusing and conflicting. The results of the much awaited randomised double-blind, placebo-controlled trial using remdesivir … Continue reading Remdesivir trial results: NEJM, NIAID and Gilead provide conflicting information
India rejects patent claims on two HIV/AIDS drugs
The Indian Patent Office (IPO) has rejected applications from two U.S. pharmaceutical companies on grounds of "evergreening", raising hopes of a further lowering of prices of two life-saving drugs used by HIV/AIDS patients in the country. U.S. drug companies, Gilead Sciences and Tibotec Pharmaceuticals, manufacturers of Tenofovir and Darunavir, respectively, lost their cases for patents … Continue reading India rejects patent claims on two HIV/AIDS drugs
Science Chronicle 